1 completed, 1 terminated. 2 Phase 1, 1 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 1 | 2 | Completed 1, Terminated 1 |
| Phase 2 | 1 | Completed 1 |
Follow Lung Infection Pseudomonal: new trials by email Literature Review of Lung Infection Pseudomonal trials Research Report on Lung Infection Pseudomonal
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Ph 1/2 Study Evaluating Safety and Tolerability of Inhaled AP-PA02 in Subjects With Chronic Pseudomonas Aeruginosa Lung Infections and Cystic Fibrosis AP-PA02, Placebo - Cystic Fibrosis, Pseudomonas Aeruginosa | Phase 1 / Phase 2 | Completed | Armata Pharmaceuticals, Inc. | 29 | 2020-12-22 | 2024-01-31 |
| A Study of the Safety and Tolerability of Inhaled SNSP113 in Healthy Subjects and Subjects With Stable Cystic Fibrosis Inhaled SNSP113, Inhaled Placebo - Lung Diseases, Pulmonary Disease | Phase 1 | Terminated | Synspira, Inc. | 32 | 2017-09-28 | 2018-05-25 |
Cystic Fibrosis (2) · Burkholderia Infections (1) · Infections (1) · Lung Diseases (1) · Mycobacterium Infections, Nontuberculous (1) · Pneumonia (1) · Pseudomonas Infections (1) · Respiratory Tract Diseases (1)
Bacterial Infections (2) · Bacterial Infections and Mycoses (2) · Congenital, Hereditary, and Neonatal Diseases and Abnormalities (2) · Digestive System Diseases (2) · Genetic Diseases, Inborn (2) · Gram-Negative Bacterial Infections (2) · Infant, Newborn, Diseases (2) · Pancreatic Diseases (2) · Actinomycetales Infections (1) · Gram-Positive Bacterial Infections (1) · Infections (1) · Lung Diseases (1) · Mycobacterium Infections (1) · Respiratory Tract Diseases (1) · Respiratory Tract Infections (1)
Armata Pharmaceuticals, Inc. (1) · Synspira, Inc. (1)
United Kingdom (1) · United States (1)
Maria Theresa Basco, MD, MPH (1) · Mina Pastagia, MD, MS (1)